References
1. Malinnikova E.Yu. New coronaviral infection. Today’s look at the pandemic of the XXI century. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 (2): 18–32. DOI: https://doi.org/10.33029/2305-3496-2020-9-2-18-32 (in Russian)
2. Drapkina O.M., Maev I.V., Bakulin I.G., Nikonov E.L., Chulanov V.P., Belousova E.A., et al. Interim guidelines «Diseases of the digestive organs in the context of a new coronavirus infection pandemic (COVID-19)». Profilakticheskaya meditsina [Preventive Medicine]. 2020; 23 (3): 2120‑52. DOI: https://doi.org/10.17116/profmed202023032120 (in Russian)
3. Arutyunov G.P., Tarlovskaya E.I., Koziolova N.A., et al. The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2. Terapevticheskiy arkhiv [Therapeutic Archive]. 2020; 92 (9): 108–24. DOI: https://doi.org/10.26442/00403660.2020.09.000703 (in Russian)
4. Singh H.O., et al. ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. Microb Pathog. 2021; 150: 104621. PMID: 33278516.
5. Abobaker A., Nagib T., Alsoufi A. The impact of certain genetic variants (single nucleotide polymorphisms) on incidence and severity of COVID-19. J Gene Med. 2021; 23 (2): e3310. PMID: 33438249.
6. Darbani B. The expression and polymorphism of entry machinery for COVID-19 in human: juxtaposing population groups, gender, and different tissues. Int J Environ Res Public Health. 2020; 17 (10): 3433. DOI: https://doi.org/10.3390/ijerph17103433
7. Guilger-Casagrande M., et al. Perspectives and challenges in the fight against COVID-19: the role of genetic variability. Front Cell Infect Microbiol. 2021; 11: 150. DOI: https://doi.org/10.3389/fcimb.2021.598875
8. Senapati S., et al. Assessment of risk conferred by coding and regulatory variations of TMPRSS2 and CD26 in susceptibility to SARS-CoV-2 infection in human. J Genet. 2020; 99: 1–5. DOI: https://doi.org/10.1007/s12041-020-01217-7
9. Hou Y., et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020; 18 (1): 1–8. DOI: https://doi.org/10.1186/s12916-020-01673-z
10. Kaidashev I., et al. Host gene variability and SARS-CoV-2 infection: a review article. Heliyon. 2021; 7 (8): e07863. DOI: https://doi.org/10.1016/j.heliyon.2021.e07863
11. Stawiski E.W., et al. Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. bioRxiv. 2020. DOI: https://doi.org/10.1101/2020.04.07.024752
12. Bosso M., et al. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol Ther Methods Clin Dev. 2020; 18: 321––7. DOI: https://doi.org/10.1016/j.omtm.2020.06.017
13. Calcagnile M., et al. ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study. bioRxiv. 2020. DOI: https://doi.org/10.1101/2020.04.23.057042
14. Wooster L., et al. Polymorphisms in the ACE2 locus associate with severity of COVID-19 infection. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.06.18.20135152
15. Hussain M., et al. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020; 92 (9): 1580–6. DOI: https://doi.org/10.1002/jmv.25832
16. Asselta R., et al. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany N.Y.). 2020; 12 (11): 10087. DOI: https://doi.org/10.18632/age.103415
17. McCoy J., et al. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020; 19 (7): 1542–643. DOI: https://doi.org/10.1111/jocd.13455
18. Wambier C.G., et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020; 81 (7): 771–6. DOI: https://doi.org/10.1002/ddr.21688
19. Ghasemzadeh A., Esfahani V. Effect of Genetic Factors on COVID-19 Susceptibility and Severity: a Review. Spring. 2021: 6 (21): 7–11. DOI: https://doi.org/10.22034/pmj.2021.244730
20. Mauvais-Jarvis F., et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020; 396 (10 250): 565–82. https://doi.org/10.1016/S0140-6736(20)31561-0
21. Stokes E.K., et al. Coronavirus disease 2019 case surveillance – United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (24): 759. https://doi.org/10.15585/mmwr.mm6924e2
22. Schurz H., et al. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genom. 2019; 13 (1): 1–12. DOI: https://doi.org/10.1186/s40246-018-0185-z
23. AL-Eitan L.N., Alahmad S.Z. Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. Rev Med Virol. 2021; 31 (4): e2194. https://doi.org/10.1002/rmv.2194
24. Mathew J., Basheeruddin K., Prabhakar S. Differences in frequency of the deletion polymorphism of the angiotensin-converting enzyme gene in different ethnic groups. Angiology. 2001; 52 (6): 375–9. DOI: https://doi.org/10.1177/000331970105200602
25. Lee Y.J., Tsai J.C.R. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patients. Diabetes Care. 2002; 25 (6): 1002–8. DOI: https://doi.org/10.2337/diacare.25.6.1002
26. Aung A.K., et al. Angiotensin converting enzyme genotypes and mortality from COVID-19: an ecological study. J Infect. 2020; 81 (6): 961–5. DOI: https://doi.org/10.1016/j.jinf.2020.11.012
27. Calabrese C., et al. ACE gene I/D polymorphism and acute pulmonary embolism in COVID-19 pneumonia: a potential predisposing role. Front Med. 2020; 7: 1136. DOI: https://doi.org/10.3389/fmed.2020.631148